Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

6 Mar 2012

Abstract excerpt

BACKGROUND: Methylation of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene promoter is a favorable prognostic factor in glioblastoma patients. However, reported methylation frequencies vary significantly partly due to lack of consensus in the choice of analytical method. METHOD: We examined 35 low- and 99 high-grade gliomas using quantitative methylation specific PCR (qMSP) and pyrosequencing. Gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22390413
DOI: 10.1186/1479-5876-10-36

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCRPMID 22390413Read ↗

Prognostic Role of Methylation Status of theMGMTPromoter Determined Quantitatively by Pyrosequencing in Glioblastoma PatientsSemantic proximity Read ↗

Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastomaSemantic proximity Read ↗

MGMT Gene Promoter Methylation Status – Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in GlioblastomasSemantic proximity Read ↗

Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastomaSemantic proximity Read ↗

Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questionsSemantic proximity Read ↗

MGMT Pyrosequencing-Based Cut-Off Methylation Level and Clinical Outcome in Patients with Glioblastoma MultiformeSemantic proximity Read ↗

Comparative analysis of pyrosequencing and next-generation sequencing for assessing MGMT methylation in glioma patientsSemantic proximity Read ↗

Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed GlioblastomaSemantic proximity Read ↗

Combining MGMT promoter pyrosequencing and protein expression to optimize prognosis stratification in glioblastomaSemantic proximity Read ↗

Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patientsSemantic proximity Read ↗

Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.Semantic proximity Read ↗

Quantitative analysis of MGMT promoter methylation status changes by pyrosequencing in recurrent glioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.